WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing
Company is among the first in China's drug-device combination products sector to obtain this certification, delivering superior solutions to global clients Zero non-conformities demonstrates company's robust quality management system SHANGHAI, April...
WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
WUXI, China, Jan. 13, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi –Drug Product Facility 5 (DP5)...
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting
SAN FRANCISCO and SUZHOU, China, March 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...